Literature DB >> 23211774

Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers.

Viktor Dahl1, Julia Peterson, Serena Spudich, Evelyn Lee, Barbara L Shacklett, Richard W Price, Sarah Palmer.   

Abstract

OBJECTIVE: Elite controllers are a rare subset of HIV-1-infected individuals who maintain HIV-1 RNA concentrations in plasma below the lower limit of quantification of clinical assays (<20-50 copies/ml) in the absence of antiretroviral therapy. Here, we examine to what extent elite controllers also control infection of the central nervous system (CNS).
DESIGN: We analysed paired cerebrospinal fluid (CSF) and plasma samples using a highly sensitive assay for HIV-1 RNA quantification.
METHODS: We analysed 28 CSF samples and 27 concurrent plasma samples from 14 elite controllers with the highly sensitive single-copy assay (SCA) that allows for HIV-1 RNA quantification down to less than one copy of HIV-1 RNA per millilitre.
RESULTS: Three samples were excluded because of internal standard failure. HIV-1 RNA was detected in only five of 26 CSF samples compared with 14 of 26 plasma samples (P = 0.02), with a median of 0.2 (range, 0.1-6) copies/ml in CSF compared with 0.8 (range, 0.1-189 copies/ml) in plasma (P < 0.0001).
CONCLUSION: HIV-1 RNA could not be detected in CSF in most elite controllers using the highly sensitive SCA, and when detected, it was at significantly lower frequencies and concentrations than in plasma. Elite controllers thus control HIV-1 in the CNS very well. Whether the infrequent and small amounts of HIV-1 RNA in the CSF reflect production from a local reservoir or virion exchange between the blood and the CSF is uncertain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23211774      PMCID: PMC4004626          DOI: 10.1097/QAD.0b013e32835cf235

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group.

Authors:  J B Hubert; M Burgard; E Dussaix; C Tamalet; C Deveau; J Le Chenadec; M L Chaix; E Marchadier; J L Vildé; J F Delfraissy; L Meyer
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

Review 2.  Toward an AIDS vaccine.

Authors:  Bruce D Walker; Dennis R Burton
Journal:  Science       Date:  2008-05-09       Impact factor: 47.728

3.  Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.

Authors:  Joel N Blankson; Justin R Bailey; Seema Thayil; Hung-Chih Yang; Kara Lassen; Jun Lai; Shiv K Gandhi; Janet D Siliciano; Thomas M Williams; Robert F Siliciano
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

5.  Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.

Authors:  Sophie Grabar; Hana Selinger-Leneman; Sophie Abgrall; Gilles Pialoux; Laurence Weiss; Dominique Costagliola
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

Review 6.  Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.

Authors:  Steven G Deeks; Bruce D Walker
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

Review 7.  Antiretroviral therapy and central nervous system HIV type 1 infection.

Authors:  Richard W Price; Serena Spudich
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

8.  A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.

Authors:  Jason B Dinoso; Scott Y Kim; Robert F Siliciano; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

9.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

View more
  12 in total

Review 1.  Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

Authors:  Suzi Hong; William A Banks
Journal:  Brain Behav Immun       Date:  2014-10-22       Impact factor: 7.217

2.  ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.

Authors:  Irini Sereti; Roy M Gulick; Sonya Krishnan; Stephen A Migueles; Adrian Palfreeman; Veronique Touzeau-Römer; Waldo H Belloso; Sean Emery; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

Review 3.  Towards an HIV-1 cure: measuring the latent reservoir.

Authors:  Katherine M Bruner; Nina N Hosmane; Robert F Siliciano
Journal:  Trends Microbiol       Date:  2015-03-05       Impact factor: 17.079

4.  Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression.

Authors:  Magnus Gisslen; Sheila M Keating; Serena Spudich; Victor Arechiga; Sophie Stephenson; Henrik Zetterberg; Clara Di Germanio; Kaj Blennow; Dietmar Fuchs; Lars Hagberg; Philip J Norris; Julia Peterson; Barbara L Shacklett; Constantin T Yiannoutsos; Richard W Price
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

5.  Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Authors:  Julia Peterson; Magnus Gisslen; Henrik Zetterberg; Dietmar Fuchs; Barbara L Shacklett; Lars Hagberg; Constantin T Yiannoutsos; Serena S Spudich; Richard W Price
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

Review 6.  Targeting the Brain Reservoirs: Toward an HIV Cure.

Authors:  Céline Marban; Faezeh Forouzanfar; Amina Ait-Ammar; Faiza Fahmi; Hala El Mekdad; Fadoua Daouad; Olivier Rohr; Christian Schwartz
Journal:  Front Immunol       Date:  2016-09-30       Impact factor: 7.561

Review 7.  Single-molecule techniques to quantify and genetically characterise persistent HIV.

Authors:  Xiao Qian Wang; Sarah Palmer
Journal:  Retrovirology       Date:  2018-01-09       Impact factor: 4.602

Review 8.  Microglial Cells: The Main HIV-1 Reservoir in the Brain.

Authors:  Clementine Wallet; Marco De Rovere; Jeanne Van Assche; Fadoua Daouad; Stéphane De Wit; Virginie Gautier; Patrick W G Mallon; Alessandro Marcello; Carine Van Lint; Olivier Rohr; Christian Schwartz
Journal:  Front Cell Infect Microbiol       Date:  2019-10-24       Impact factor: 5.293

9.  Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.

Authors:  Anupama Ganesh; Donna Lemongello; Evelyn Lee; Julia Peterson; Bridget E McLaughlin; April L Ferre; Geraldine M Gillespie; Dietmar Fuchs; Steven G Deeks; Peter W Hunt; Richard W Price; Serena S Spudich; Barbara L Shacklett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-02       Impact factor: 2.205

10.  Markers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL.

Authors:  Shelli F Farhadian; Hetal Mistry; Tobias Kirchwey; Jennifer Chiarella; Rachela Calvi; Michelle Chintanaphol; Payal Patel; Marie L Landry; Kevin Robertson; Serena S Spudich
Journal:  Open Forum Infect Dis       Date:  2019-12-14       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.